



Pureos Bioventures welcomes Dr. Lars Nieba to its team as venture partner

Pfäffikon, Switzerland, 9 November 2021

Pureos Bioventures, a venture capital fund dedicated to support private biotech companies developing novel therapies, announced the appointment of Dr. Lars Nieba as venture partner to its team. The first-time fund has USD 205 million under management and has invested in 11 private biotech companies so far. In addition, Pureos is a partner at BaseLaunch, an incubator of biotech startups in Basel, Switzerland. First portfolio companies of Pureos Bioventures have already gone public or have been acquired.

As of November, Dr. Lars Nieba is supporting Pureos as new venture partner. Lars brings more than 20 years of leadership experience in the development of several pharmaceutical products and innovative technologies. Lars is Chief Technology Officer at Nordic Nanovector, a biotech company developing novel radio-immunoconjugates for treating cancers. Previously, Lars was VP and Strategic Product Lead at Bayer. Before that Lars held several leadership roles at F. Hoffmann-La Roche responsible for clinical supply planning, biologics technology and technical business development biologics. Lars gained his PhD from the Max-Planck-Institute for Biochemistry, Munich, and Institute for Biochemistry at the University of Zürich; he also holds an executive MBA from the University of St. Gallen, Switzerland.

Managing Partners of Pureos Klaus Breiner, Dominik Escher, and Martin Münchbach stated: “We are very pleased to welcome Lars as an additional venture partner at Pureos. Lars brings an outstanding experience in developing biological pharmaceutical products from discovery to commercialization. This broad experience is very rare in the biotechnology industry and many of our portfolio companies will benefit from his broad experience.”

###

About Pureos Bioventures

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

For more information visit www.pureosbio.com

Contact

Dr. Klaus Breiner

Klaus.breiner@pureosbio.com

Dr. Dominik Escher

Dominik.escher@pureosbio.com

Dr. Martin Münchbach

Martin.muenchbach@pureosbio.com

Pureos Partners AG

Churerstrasse 47

8808 Pfäffikon/SZ

Switzerland